Business
Faron to Present at Upcoming Conferences
Faron to Present at Upcoming Conferences.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \n \n Faron Pharmaceuticals \n Ltd.\n \n \n (\"Faron\" or \"Company\")\n \n \n \n \n \n Faron to Present at Upcoming Conferences\n \n \n \n \n \n \n Press Release, September 7, 2022 at 08:00 AM (EDT) / 01:00 PM (BST) / 03:00 PM (EEST)\n \n \n \n \n \n \n TURKU, FINLAND / BOSTON, MA\n - Faron Pharmaceuticals Ltd.\n (\n AIM: FARN, First North: FARON\n )\n , \n a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation\n , \n today announced that members of the Company's senior leadership team will participate in fireside chats at the following conferences in September:\n \n \n \n \n \n ·\n H. C. Wainwright Global Investment Conference - Monday, September 12\n \n \n ·\n R.W. Baird Global Healthcare Conference - Tuesday, September 13\n \n \n \n \n \n Recordings of available presentations will be added to the \"Investor\"\n section on Faron's website at \n \n https://www.faron.com/investors\n \n .\n \n \n \n \n \n \n For more information please contact:\n \n \n \n \n \n \n \n \n \n Investor Contact\n \n \n \n \n Faron Pharmaceuticals\n \n \n \n Julia Balanova\n \n \n VP, Investor Relations\n \n \n \n [email protected]\n \n \n \n \n [email protected]\n \n \n \n Phone: +1 (917) 306-6096\n \n \n \n \n \n \n \n \n Media Contact\n \n \n \n \n Faron Pharmaceuticals\n \n \n \n Eric Van Zanten\n \n \n VP, Communications\n \n \n \n [email protected]\n \n \n \n Phone: +1 (610) 529-6219\n \n \n \n \n \n \n \n \n \n About Faron Pharmaceuticals Ltd.\n \n \n \n \n Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients w...